NEUROCRINE BIOSCIENCES INC (NBIX) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 1054 transactions totaling $518.0M, demonstrating a bearish sentiment with -$518.0M in net insider flow. The most recent transaction on Feb 20, 2026 involved a transaction of 3,110 shares valued at $0.
No significant insider buying has been recorded for NBIX in the recent period.
No significant insider selling has been recorded for NBIX in the recent period.
Based on recent SEC filings, insider sentiment for NBIX is bearish with an Insider Alignment Score of 0/100 and a net flow of -$518.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at NEUROCRINE BIOSCIENCES INC (NBIX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading NBIX stock, having executed 1054 transactions in the past 90 days. The most active insider is Kevin Charles Gorman (Executive), who has made 81 transactions totaling $128.6M.
Get notified when executives and directors at NBIX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | Onyia Jude | Chief Scientific Officer | Gift | 3,110 | $N/A | $0 | |
| Jan 31, 2026 | Benevich Eric | Chief Commercial Officer | Option Exercise | 2,294 | $N/A | $0 | |
| Jan 31, 2026 | Benevich Eric | Chief Commercial Officer | Payment | 1,292 | $136.06 | $175.8K | |
| Jan 31, 2026 | Benevich Eric | Chief Commercial Officer | Option Exercise | 2,294 | $N/A | $0 | |
| Jan 31, 2026 | W. Boyer David | Chief Corp. Affairs Officer | Option Exercise | 2,096 | $N/A | $0 | |
| Jan 31, 2026 | W. Boyer David | Chief Corp. Affairs Officer | Payment | 1,189 | $136.06 | $161.8K | |
| Jan 31, 2026 | W. Boyer David | Chief Corp. Affairs Officer | Option Exercise | 2,096 | $N/A | $0 | |
| Jan 31, 2026 | Onyia Jude | Chief Scientific Officer | Option Exercise | 238 | $N/A | $0 | |
| Jan 31, 2026 | Onyia Jude | Chief Scientific Officer | Payment | 142 | $136.06 | $19.3K | |
| Jan 31, 2026 | Onyia Jude | Chief Scientific Officer | Option Exercise | 238 | $N/A | $0 | |
| Jan 31, 2026 | Lippoldt Darin | Chief Legal Officer | Option Exercise | 2,373 | $N/A | $0 | |
| Jan 31, 2026 | Lippoldt Darin | Chief Legal Officer | Payment | 1,335 | $136.06 | $181.6K | |
| Jan 31, 2026 | Lippoldt Darin | Chief Legal Officer | Option Exercise | 2,373 | $N/A | $0 | |
| Jan 31, 2026 | Charles Gorman Kevin | Executive | Option Exercise | 5,142 | $N/A | $0 | |
| Jan 31, 2026 | Charles Gorman Kevin | Executive | Payment | 2,845 | $136.06 | $387.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 682 | $518.0M | 82.5% |
Exercise(M) | 327 | $106.0M | 16.9% |
Payment(F) | 35 | $3.8M | 0.6% |
Gift(G) | 10 | $0 | 0.0% |
Insider selling pressure at NEUROCRINE BIOSCIENCES INC has increased, with 26 insiders executing 1054 transactions across all time. Total sales of $518.0M significantly outpace purchases of $0, resulting in a net outflow of $518.0M. This selling activity appears largely discretionary, which may warrant closer attention from investors.